Date published: 2026-3-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

DOCK 4 Inhibitors

DOCK (Dedicator of Cytokinesis) family of proteins, with a particular focus on DOCK 4. The DOCK family, which stands for the dedicator of cytokinesis, consists of guanine nucleotide exchange factors (GEFs) that play a crucial role in regulating intracellular signaling pathways. DOCK 4, as a member of this family, is implicated in the modulation of cellular processes such as cytoskeletal rearrangement, cell migration, and cell adhesion. The inhibitors designed for DOCK 4 act by disrupting the GEF activity of the protein, thereby influencing downstream signaling cascades.

DOCK 4 inhibitors are carefully crafted compounds designed to fit into the active site of the DOCK 4 protein, hindering its ability to catalyze the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on target small GTPases. This interference in the nucleotide exchange process serves as a molecular switch, modulating the activity of downstream signaling pathways that are intricately involved in cellular dynamics. By selectively targeting DOCK 4, these inhibitors have the potential to influence cellular processes related to cell motility, a characteristic that holds significance in various physiological and pathological contexts, including development, immune response, and cancer metastasis. The development of DOCK 4 inhibitors represents a nuanced approach to manipulating cellular signaling, shedding light on the intricate molecular mechanisms that govern cellular behavior.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a potent and irreversible inhibitor of PI3K, which can indirectly inhibit DOCK4 by blocking phosphoinositide 3-kinase, part of the signaling pathway that DOCK4 is involved in.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a Src inhibitor. DOCK4 interacts with Src family kinases, and inhibition of these kinases can indirectly reduce DOCK4 activity.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$94.00
$227.00
30
(1)

PP 2 is a selective Src family kinase inhibitor. It can indirectly inhibit DOCK4 by blocking the activity of Src kinases.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin is an mTOR inhibitor that can indirectly inhibit DOCK4 by limiting mTOR signaling, a pathway that DOCK4 can also influence.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$104.00
$141.00
14
(1)

Triciribine is an Akt inhibitor. By suppressing Akt, it can indirectly limit the activity of DOCK4.

AZD8055

1009298-09-2sc-364424
sc-364424A
10 mg
50 mg
$163.00
$352.00
12
(2)

AZD8055 is a potent mTOR inhibitor that can indirectly inhibit DOCK4 by suppressing mTOR signaling.

GSK 690693

937174-76-0sc-363280
sc-363280A
10 mg
50 mg
$255.00
$1071.00
4
(1)

GSK690693 is an Akt inhibitor. It can indirectly inhibit DOCK4 by limiting Akt-mediated signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059 is a selective MEK inhibitor. It can indirectly inhibit DOCK4 by blocking the ERK pathway, which DOCK4 can utilize.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor. It can indirectly inhibit DOCK4 by suppressing JNK signaling, a pathway that DOCK4 can influence.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 is a p38 MAPK inhibitor. It can indirectly inhibit DOCK4 by limiting p38 MAPK signaling.